Document is current
Any future updates will be listed below
-
Authors
Wendlinger, Lennard https://orcid.org/0009-0005-4519-7972
Parzinger, Mara
Litvinenko, Alexandra https://orcid.org/0000-0002-5070-7122
Viertl, David https://orcid.org/0000-0001-5203-0939
Spatz, Philipp https://orcid.org/0000-0003-1718-5593
Wurzer, Alexander https://orcid.org/0000-0002-3628-4688
Wester, Hans-Jürgen https://orcid.org/0000-0002-6655-4183
Schottelius, Margret https://orcid.org/0000-0002-1928-6913
-
Funding
Funding for this research was provided by:
University of Lausanne
- License Information
-
More Information
Article History
Received: 14 May 2025
Accepted: 14 October 2025
First Online: 23 October 2025
Declarations
:
: All animal experiments were conducted in compliance with the ARRIVE guidelines and according to the general animal welfare regulations in Germany or Switzerland (German animal protection act, as amended on 18.05.2018, Art. 141 G v. 29.3.2017 I 626, approval no. 55.2-1-54-2532-71-13 by the General Administration of the Free State of Bavaria; Swiss animal welfare regulations: Animal Welfare Act SR 455, license: Canton de Vaud, 3781 d).
: Not applicable.
: The authors LW, MP, and HJW are listed as inventors on the patent EP2022/071964 “Ligand compounds comprising a chelating group as a bridging unit”. PS is employed by, and HJW is founder, shareholder, and scientific advisor of Scintomics att GmbH, which is IP holder for rhTATE (termed [Ga]rhTATE2.5 in this work).
